Huaguan Biotech announced the completion of hundreds of millions of yuan in Series C financing.

Recently, Beijing Huaguan Biotechnology Co., Ltd. (hereinafter referred to as "Huaguan Biotech"), a leading domestic manufacturer in synthetic biology and green chemical production, officially announced the completion of a Series C financing of hundreds of millions of RMB. This round of financing was jointly invested by institutions such as SoftBank Xinchuang, Shunxi Fund, Changzhou Qihang Synthetic Biology Venture Capital Fund, SDIC Chuangyi, and Yangtze River Capital. Light Source Capital served as the financial advisor. The funds raised will be mainly used for the R & D of new products in the pharmaceutical and health - care fields, the expansion of production bases, and the establishment of an innovation cooperation platform, injecting strong impetus into the company's next - stage development.

As a typical representative of new - quality productivity in the high - end manufacturing field, the synthetic biology and green chemistry industry is at a critical stage of industrial upgrading. The industry's requirements for safety and compliance, environmental protection efficiency, and cost optimization are increasing day by day. As a leading domestic manufacturer in synthetic biology and green chemical production, Huaguan Biotech, leveraging its dual advantages in enzymatic chemical synthesis and continuous - flow technology, has established a full - chain technology system covering enzyme screening, synthesis process optimization, pilot - scale and large - scale production, continuously promoting the green development of the high - end manufacturing field.

In terms of core technology layout, Huaguan Biotech has built a resource library of tens of thousands of catalytic enzymes, forming a complete technology closed - loop of "directed evolution - rational design - discovery of new enzymes - high - density fermentation - purification and immobilization". The enzyme - catalyzed system has advantages such as high reaction efficiency and high product purity. In terms of continuous - flow technology, the company's self - designed microchannels and micro - packed bed reactors have achieved safe and controllable, efficient mixing, and rapid scale - up of the reaction process, providing solid support for industrial safe production.

Currently, Huaguan Biotech has established R & D centers in Beijing, Nanjing and other places, and has a 100 - ton - scale GMP production base covering an area of over 61,000 square meters in Inner Mongolia to fully guarantee production capacity. The company is simultaneously promoting the expansion of new production capacity to further meet market demand. Its core products cover pharmaceutical fields such as cardiovascular and cerebrovascular diseases and anti - infection, as well as health - care fields such as anti - aging and medical aesthetics. Among them, key products such as Edoxaban, Piroctone, and GCLE have achieved an annual production capacity ranging from tons to hundreds of tons. With excellent product quality and cost advantages, the company has established long - term and stable cooperative relationships with many leading enterprises in the industry.

Facing the future, Huaguan Biotech will continuously focus on the industrial chain upgrade of upstream APIs and their key intermediates, break through the traditional "contract execution" model of CDMO, and cooperate precisely with downstream formulation commercialization partners to create a new model of precise innovation cooperation featuring deep integration, risk sharing, and result sharing.

Dr. Chen Jian, Chairman of Huaguan Biotech, said: "Synthetic biology is currently a hot topic in the entire industry. In particular, 'replacing God' to create new substances and 'helping God' to move natural products from nature to factories for functional and industrial upgrades have infinite possibilities. However, in the pharmaceutical field, more drug molecules have been deeply optimized by humans based on effectiveness and safety. The application scenarios of simply using synthetic biology for industrial upgrading account for less than one - third. Huaguan Biotech focuses on the upstream, builds a dual - technology platform of green chemistry and synthetic biology, realizes GMP - compliant green and safe production and cost reduction of more pharmaceutical products, and precisely serves downstream formulation partners to achieve long - term companionship and common development in the new PDMO (Partnered Development & Manufacture Organization) model."

Mr. Ren Peng, Chairman and General Manager of Shunxi Management Company under Beijing State - owned Assets Management Co., Ltd., said: "The Beijing Medical and Health Fund and the Beijing New Materials Fund have always been optimistic about excellent enterprises that promote high - quality industrial development through technological innovation. Huaguan Biotech has been deeply involved in the synthetic biology and green chemistry track. The resource library of tens of thousands of catalytic enzymes it has built and the self - developed reactor technology provide core support for the green and safe production of pharmaceutical products. This round of financing will help the company accelerate production capacity expansion and new product R & D. We believe that Huaguan Biotech can lead industry transformation through technological breakthroughs and contribute to the innovative development of the synthetic biology industry."

Wang Chunping, Partner of Changzhou Qihang Synthetic Biology Venture Capital Fund, said: "As an industrial investment platform focusing on cutting - edge biotechnology, Qihang Investment has always been concerned about innovative enterprises with technological originality and industrialization capabilities. Huaguan Biotech is deeply rooted in the fields of synthetic biology and green chemistry. The full - chain technology system of enzymatic and continuous - flow and GMP production capacity it has built are highly in line with the core needs of the pharmaceutical and health - care industries for safety, efficiency, and low cost. We firmly believe that Huaguan Biotech can drive industrial chain upgrade through technological innovation, become an industry model under the background of new - quality productivity, and inject new impetus into the development of the regional biomedical industry."

Hong Lei, Head of the Medical Department and Managing Director of Light Source Capital, said: "Congratulations to Huaguan Biotech on successfully completing the Series C financing. We are honored to join hands with Dr. Chen and his team to help the company set a new industry benchmark in the wave of China's bio - manufacturing upgrade. Against the backdrop of the global bio - manufacturing transformation towards green and efficient development, Huaguan Biotech, with enzymatic chemical synthesis and continuous - flow technology as the core, has established a complete industrial closed - loop from technology R & D to commercial production. We look forward to Dr. Chen leading the team to achieve new leaps under the innovative cooperation model."